

DEC. 23. 2005 12:35PM

AVENTIS US PAT DEPT

NO. 0811 P. 1

RECEIVED  
CENTRAL FAX CENTER

DEC 23 2005

PTO/SB/21 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE**TRANSMITTAL  
FORM**

|   |         |                        |                        |
|---|---------|------------------------|------------------------|
| <i>(to be used for all correspondence after initial filing)</i> |         | Application Number     | 10/786,810             |
|   |         | Filing Date            | February 25, 2004      |
|   |         | First Named Inventor   | Jesús BENAVIDES et al. |
|   |         | Art Unit               | 1617                   |
|   |         | Examiner Name          | CHONG, Yong Soo        |
| Total Number of Pages in This Submission                        | 15 pgs. | Attorney Docket Number | ST01029 US CNT         |

**ENCLOSURES (Check all that apply)**

|  |   |   |
|--|---|---|
| <input type="checkbox"/> Fee Transmittal Form  | <input type="checkbox"/> Drawing(s)                                       | <input type="checkbox"/> After Allowance Communication to TC                            |
| <input type="checkbox"/> Fee Attached  | <input type="checkbox"/> Licensing-related Papers                         | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences     |
| <input type="checkbox"/> Amendment/Reply   | <input type="checkbox"/> Petition   | <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final   | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Proprietary Information  |
| <input type="checkbox"/> Affidavits/declaration(s)   | <input type="checkbox"/> Power of Attorney, Revocation                    | <input type="checkbox"/> Status Letter  |
| <input type="checkbox"/> Extension of Time Request   | <input type="checkbox"/> Change of Correspondence Address                 | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):         |
| <input type="checkbox"/> Express Abandonment Request   | <input type="checkbox"/> Terminal Disclaimer                              | <input type="checkbox"/> 1. Response to Restriction/Election requirement - 7pgs.        |
| <input type="checkbox"/> Information Disclosure Statement  | <input type="checkbox"/> Request for Refund                               | <input type="checkbox"/> 2. Copy of the International Preliminary Examination - 7 pgs.  |
| <input type="checkbox"/> Certified Copy of Priority Document(s)                                    | <input type="checkbox"/> CD, Number of CD(s) _____                        |   |
| <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application                            | <input type="checkbox"/> Landscape Table on CD                            |   |
| <input type="checkbox"/> <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 |   |   |
| Remarks  |   |   |

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

|              |                              |          |        |
|--------------|------------------------------|----------|--------|
| Firm Name    | AVENTIS PHARMACEUTICALS INC. |          |        |
| Signature    |                              |          |        |
| Printed name | Balaram GUPTA                |          |        |
| Date         | December 23, 2005            | Reg. No. | 40,009 |

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300 ; Total No. of Pages Transmitted: 15 pgs.)

Signature

Typed or printed name

Maribel Mendez

Date

December 23, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**PATENT**

Docket No.: ST01023 US CNT

RECEIVED  
CENTRAL FAX CENTER**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

DEC 23 2005

In re Application of  
Jesus Benavides, et al.

Examiner: Chong, Yong Soo

Serial No.: 10/786,810

Art Unit: 1617

Filed: February 25, 2004

**TELEFAX CERTIFICATE**

Title: Combination of a CB1 Receptor Antagonist and of a Product which Activates Dopaminergic Neurotransmission in the Brain, the Pharmaceutical Compositions Comprising Them and Their Use in the Treatment of Parkinson's Disease

I hereby certify that this correspondence is being transmitted via facsimile at (571) 273-8300 to the Commissioner for Patents, Washington, D.C. 20231, on

December 23, 2005

Date of transmission  
*Theresa Mendieta*  
Signature

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Response to Restriction/Election Requirement Under 35 U.S.C. § 121**

Sir:

This is in response to the Office Action, dated, November 30, 2005, having a response due by December 30, 2005 in the above-identified patent application. It is respectfully requested that the following provisional election, and the remarks be entered in this case.

**PROVISIONAL ELECTION:**

Applicants provisionally elect with traverse the invention Group VII, claims 1, 2 (in part), 10, 20, 21 (in part), 29, and 35-36, drawn to a composition comprising levodopa and a compound of formula I where R comprises an aryl group such as N-[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-N-(3,5-difluorophenyl)methylsulfonamide.